Literature DB >> 23503426

Neuroendocrine differentiation of prostate cancer.

Zhen Li1, Clark J Chen, Jason K Wang, Elaine Hsia, Wei Li, Jill Squires, Yin Sun, Jiaoti Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23503426      PMCID： PMC3739654          DOI： 10.1038/aja.2013.7

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  30 in total

1.  Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate.

Authors:  Jennifer R Brown; Tad J Wieczorek; Kitt Shaffer; Ravi Salgia
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

2.  Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP.

Authors:  Kohsuke Uchida; Naoya Masumori; Atsushi Takahashi; Naoki Itoh; Kazunori Kato; Robert J Matusik; Taiji Tsukamoto
Journal:  Prostate       Date:  2006-04-01       Impact factor: 4.104

3.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Authors:  Hongbing Chen; Yin Sun; Chengyu Wu; Clara E Magyar; Xinmin Li; Liang Cheng; Jorge L Yao; Steven Shen; Adeboye O Osunkoya; Chaozhao Liang; Jiaoti Huang
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

4.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Authors:  Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 6.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.

Authors:  Nadezda Vashchenko; Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2005-02       Impact factor: 20.096

7.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.

Authors:  Anna V Lapuk; Chunxiao Wu; Alexander W Wyatt; Andrew McPherson; Brian J McConeghy; Sonal Brahmbhatt; Fan Mo; Amina Zoubeidi; Shawn Anderson; Robert H Bell; Anne Haegert; Robert Shukin; Yuzhuo Wang; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Yongjun Zhao; Marco A Marra; Andrea Fanjul; Christopher A Maher; Arul M Chinnaiyan; Mark A Rubin; Himisha Beltran; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-07       Impact factor: 7.996

8.  CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor.

Authors:  J Reiland; L T Furcht; J B McCarthy
Journal:  Prostate       Date:  1999-10-01       Impact factor: 4.104

9.  Immunohistochemical characterization of neuroendocrine cells in prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; P Anthony di Sant'Agnese; Qi Yang; Patricia A Bourne; Yanqun Na
Journal:  Prostate       Date:  2006-09-15       Impact factor: 4.104

10.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104
View more
  17 in total

1.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

2.  Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.

Authors:  Qiang Dang; Lei Li; Hongjun Xie; Dalin He; Jiaqi Chen; Wenbing Song; Luke S Chang; Hong-Chiang Chang; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

3.  Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Authors:  P J Paul; D Raghu; A-L Chan; T Gulati; L Lambeth; E Takano; M J Herold; J Hagekyriakou; R L Vessella; C Fedele; M Shackleton; E D Williams; S Fox; S Williams; S Haupt; C Gamell; Y Haupt
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

4.  Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.

Authors:  Aaron M Udager; Yang Shi; Scott A Tomlins; Ajjai Alva; Javed Siddiqui; Xuhong Cao; Kenneth J Pienta; Hui Jiang; Arul M Chinnaiyan; Rohit Mehra
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

Review 5.  The molecular basis for ethnic variation and histological subtype differences in prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein; Jiaoti Huang
Journal:  Sci China Life Sci       Date:  2013-07-13       Impact factor: 6.038

6.  Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Authors:  Nitin Patel; Tatsuo Itakura; Shinwu Jeong; Chun-Peng Liao; Pradip Roy-Burman; Ebrahim Zandi; Susan Groshen; Jacek Pinski; Gerhard A Coetzee; Mitchell E Gross; M Elizabeth Fini
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

Review 7.  Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

8.  SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Authors:  Murali Gururajan; Karen A Cavassani; Margarit Sievert; Peng Duan; Jake Lichterman; Jen-Ming Huang; Bethany Smith; Sungyong You; Srinivas Nandana; Gina Chia-Yi Chu; Sheldon Mink; Sajni Josson; Chunyan Liu; Matteo Morello; Lawrence W M Jones; Jayoung Kim; Michael R Freeman; Neil Bhowmick; Haiyen E Zhau; Leland W K Chung; Edwin M Posadas
Journal:  Oncotarget       Date:  2015-12-29

9.  FOXA1 inhibits prostate cancer neuroendocrine differentiation.

Authors:  J Kim; H Jin; J C Zhao; Y A Yang; Y Li; X Yang; X Dong; J Yu
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

10.  GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.

Authors:  Meixiang Sang; Mohit Hulsurkar; Xiaochong Zhang; Haiping Song; Dayong Zheng; Yan Zhang; Min Li; Jianming Xu; Songlin Zhang; Michael Ittmann; Wenliang Li
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.